메뉴 건너뛰기
Archives of Pharmacal Research
Volumn 31, Issue 9, 2008, Pages 1200-1204
Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats
Author keywords

CYP3A4; Norverapamil; Pharmacokinetics; Pioglitazone; Verapamil
Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P 450 3A4, RAT; CYTOCHROME P-450 3A4, RAT; CYTOCHROME P450; DRUG DERIVATIVE; NORVERAPAMIL; PIOGLITAZONE; VERAPAMIL;
EID: 52649145848     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-001-1289-z     Document Type: Article
Times cited : (11)
References (17)
  • 1
    • 0142106303 scopus 로고    scopus 로고
    • Transporter-enzyme interactions: Implications for predicting drug-drug interactions from in vitro data
    • L. Z. Benet C. L. Cummins C. Y. Wu 2003 Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data Curr. Drug. Metab. 4 393 398
    • (2003) Curr. Drug. Metab. , vol.4 , pp. 393-398
    • Benet, L.Z.1    Cummins, C.L.2    Wu, C.Y.3
  • 2
    • 0029591169 scopus 로고
    • Cytochromes of the 450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans
    • D. Busse J. Cosme P. Beaune H. K. Kroemer M. Eichelbaum 1995 Cytochromes of the 450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans Naunyn Schmiedebergs Arch. Pharmacol. 353 116 121
    • (1995) Naunyn Schmiedebergs Arch. Pharmacol. , vol.353 , pp. 116-121
    • Busse, D.1    Cosme, J.2    Beaune, P.3    Kroemer, H.K.4    Eichelbaum, M.5
  • 3
    • 0035205594 scopus 로고    scopus 로고
    • A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus
    • J. Chilcott P. Tappenden M. L. Jones J. P. Wight 2001 A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus Clin. Ther. 23 1792 1823
    • (2001) Clin. Ther. , vol.23 , pp. 1792-1823
    • Chilcott, J.1    Tappenden, P.2    Jones, M.L.3    Wight, J.P.4
  • 4
    • 0036175307 scopus 로고    scopus 로고
    • Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4
    • C. L. Cummins W. Jacobsen L. Z. Benet 2002 Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4 J. Pharmacol. Exp. Ther. 300 1036 1045
    • (2002) J. Pharmacol. Exp. Ther. , vol.300 , pp. 1036-1045
    • Cummins, C.L.1    Jacobsen, W.2    Benet, L.Z.3
  • 5
    • 0021287002 scopus 로고
    • Pharmacokinetics of (+)-, (-)-and (±)-verapamil after intravenous administration
    • M. Eichelbaum G. Mikus B. Vogelgesang 1984 Pharmacokinetics of (+)-, (-)-and (±)-verapamil after intravenous administration Brit. J. Clin. Pharmacol. 17 453 458
    • (1984) Brit. J. Clin. Pharmacol. , vol.17 , pp. 453-458
    • Eichelbaum, M.1    Mikus, G.2    Vogelgesang, B.3
  • 7
    • 0017432208 scopus 로고
    • Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle
    • A. Fleckenstein 1977 Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle Ann. Rev. Pharmacol. Toxicol. 17 149 166
    • (1977) Ann. Rev. Pharmacol. Toxicol. , vol.17 , pp. 149-166
    • Fleckenstein, A.1
  • 9
    • 33644817278 scopus 로고    scopus 로고
    • Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide
    • L. I. Kajosaari T. Jaakkola P. J. Neuvonen J. T. Backman 2006 Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide Eur. J. Clin. Pharmacol. 62 217 223
    • (2006) Eur. J. Clin. Pharmacol. , vol.62 , pp. 217-223
    • Kajosaari, L.I.1    Jaakkola, T.2    Neuvonen, P.J.3    Backman, J.T.4
  • 10
    • 0033833913 scopus 로고    scopus 로고
    • Faster clearance of sustained release verapamil in men versus women: Continuing observations on sex-specific differences after oral administration of verapamil
    • M. E. Krecic-Shepard C. R. Barnas J. Slimko J. B. Schwartz 2000 Faster clearance of sustained release verapamil in men versus women: Continuing observations on sex-specific differences after oral administration of verapamil Clin. Pharmacol. Ther. 68 286 292
    • (2000) Clin. Pharmacol. Ther. , vol.68 , pp. 286-292
    • Krecic-Shepard, M.E.1    Barnas, C.R.2    Slimko, J.3    Schwartz, J.B.4
  • 13
    • 0020965053 scopus 로고
    • LAGRAN program for area and moments in pharmacokinetic analysis
    • M. L. Rocci W. J. Jusko 1983 LAGRAN program for area and moments in pharmacokinetic analysis Computer Programs in Biomedicine 16 203 209
    • (1983) Computer Programs in Biomedicine , vol.16 , pp. 203-209
    • Rocci, M.L.1    Jusko, W.J.2
  • 16
    • 0029028792 scopus 로고
    • Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
    • V. J. Wacher C. Y. Wu L. Z. Benet 1995 Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy Mol. Carcinog. 13 129 134
    • (1995) Mol. Carcinog. , vol.13 , pp. 129-134
    • Wacher, V.J.1    Wu, C.Y.2    Benet, L.Z.3
  • 17
    • 14044256740 scopus 로고    scopus 로고
    • Examination of 209 drugs for inhibition of cytochrome P450 2C8
    • R. L. Walsky E. A. Gaman R. S. Obach 2005 Examination of 209 drugs for inhibition of cytochrome P450 2C8 J. Clin. Pharmacol. 45 68 78
    • (2005) J. Clin. Pharmacol. , vol.45 , pp. 68-78
    • Walsky, R.L.1    Gaman, E.A.2    Obach, R.S.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.